Navigation Links
Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
Date:11/7/2013

past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures.   Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market.  Our business may be impacted by government investigations, litigation and product liability claims.  If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions.  We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement.  Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products.  In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products.  We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete a
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 2015 Seoul Semiconductor (CEO: Chung-hoon ... technology, on May 28th announced that it will ... strengthening its high efficient and high reliable LED ... 2011 Seoul Semiconductor has developed efficient and reliable ... has supplied LEDs for headlamps to global auto ...
(Date:5/28/2015)... 28, 2015 ... announced the addition of Jain PharmaBiotech,s ... Markets and Companies"  to their offering.  ... describes and evaluates animal biotechnology and ... pharmaceuticals as well as improvement in ...
(Date:5/28/2015)... IN (PRWEB) May 28, 2015 The Academy ... National Model Aviation Day on August 15, 2015. National Model ... aviation nation-wide and to introduce model flying to the general ... 2,350 chartered clubs to participate in the celebration by hosting ... registered to host National Model Aviation Day events. View ...
(Date:5/28/2015)... , May 28, 2015  PDS Biotechnology ... cancer immunotherapy treatment targeting HPV-16, has generated strong ... Currently, pre-cervical cancer is treated by surgical ... simple and effective non-surgical alternative. Results show that ... (T-cells) to recognize, target, and kill precancerous and ...
Breaking Biology Technology:Seoul Semiconductor Increases the Global Automotive LED Market Share with its High Efficient and Reliable LEDs for Automotive Lightings 2Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024 2Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024 3Model flying pilots celebrate the Academy of Model Aeronautics Foundation’s Third Annual National Model Aviation Day 2PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2
... BOTHELL, WA and VANCOUVER, July 20 /PRNewswire-FirstCall/ - OncoGenex ... it has entered into purchase agreements with certain institutional ... common stock at a price of $20 per share ... to provide gross proceeds of $9.5 million to OncoGenex ...
... , , ST. LOUIS, July 20 ... first outpatient single-site laparoscopic gastric banding surgery in the state of Missouri ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/20080812/CLTU111LOGO ... For single-site surgery, the major incision is through the belly button only. ...
... , NEWPORT, R.I., July 20 iSource ... today that it will partner with inVentiv Health, the ... to develop an innovative new technology platform that will ... to better manage their health. The platform will be ...
Cached Biology Technology:OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock 2OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock 3Surgeon Performs First Single Incision Peri-Umbilical Laparoscopic Surgery in the State of Missouri 2iSource Networks Partners with inVentiv Health to Develop New Technology Platform for Reaching Healthcare Consumers 2iSource Networks Partners with inVentiv Health to Develop New Technology Platform for Reaching Healthcare Consumers 3
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. today ... (FIDO ® ) Alliance tm , an industry ... members commit to share technology and collaborate to ... are interoperable, more secure and private, and easier ... identity verification that protects sensitive user information and ...
(Date:4/13/2015)... April 13, 2015 According ... "Global Biometrics Market Forecast & Opportunities, 2020", the global ... of around 14% till 2020. The biometrics market ... scale implementation and review of biometric management systems. ... new products with greater efficiency, are resulting in ...
(Date:4/10/2015)... 10, 2015 Research and Markets ... "Security Competitive Profiles - NEC" report to ... NEC will continue to supply a range of ... with a company focus on the development of a ... Winning opportunities in the Asia-Pacific ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2
... of scientists has released data indicating that greenhouse gas ... of methane emissions from freshwater areas. John Downing, ... and organismal biology department, is part of an international ... is higher than previous estimates. The study, ...
... a significant step forward in understanding the atmosphere,s ... some other gases, except carbon dioxide. The issue ... studies suggesting the self-cleaning power of the atmosphere ... others suggest greater stability. And what researchers are ...
... 6, 2011 Acceleron Pharma, Inc., a biopharmaceutical company ... and tissues including muscle, bone, fat, red blood cells ... a $1.5 million grant from the Muscular Dystrophy Association ... Dystrophy (DMD), a disabling neuromuscular disease in which patients ...
Cached Biology News:Freshwater methane release changes greenhouse gas equation 2NOAA-led team measures atmosphere's self-cleaning capacity 2NOAA-led team measures atmosphere's self-cleaning capacity 3Acceleron awarded $1.5 million grant from Muscular Dystrophy Association to support ACE-031 2